Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

By M. Geyer, K. Krebs-Thomson, David L. Braff, N. Swerdlow. Psychopharmacology, 2001

647 citations recorded by the source corpus.

Subfields: Biological Psychiatry, Cellular and Molecular Neuroscience, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/4e1bed0bf2b0b129a3b1c13b541a2d08832b9adb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biological Psychiatry

1. David E. Nichols
2. Bruno van Swinderen
3. B. van Alphen

In Cellular and Molecular Neuroscience

1. David E. Nichols
2. Bruno van Swinderen
3. B. van Alphen

In Psychiatry and Mental health

1. Bruno van Swinderen
2. B. van Alphen

Citations in the corpus

• Drosophila strategies to study psychiatric disorders. (2013, methodology): “PPI is impaired in patients with schizophrenia [21,64,157] and is a widely used endophenotype in rodent models of schizophrenia.”
• Psychedelics (2016, background): “To provide a bit more specific detail here, the actions of psychedelics such as DOI, psilocybin, and LSD have been considered to model, to a certain extent, some of the positive symptoms of schizophrenia (see reviews by Vollenweider et al., 1998; Geyer et al., 2001; Vollenweider, 2001; Vollenweider ”